Final answer:
Jardiance is not recommended for use in patients with an eGFR below 30 mL/min/1.73 m2 due to reduced efficacy and increased risk of side effects. It is essential to monitor renal function and choose suitable treatments for glycemic control in type 2 diabetes patients with impaired kidney function.
Step-by-step explanation:
Jardiance is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 for glycemic control in type 2 diabetes.In the management of type 2 diabetes, Jardiance (empagliflozin) is an oral diabetes medication that inhibitors. This drug assists in controlling blood sugar levels by helping the kidneys get rid of glucose from the bloodstream through urine. However, its prescriptive use is dependent on the patient's renal function, which is assessed by the eGFR – a measure of how well the kidneys filter waste from the blood.
When a patient's eGFR is lower than the recommended threshold, the efficiency of Jardiance in lowering blood glucose diminishes, and the risk of side effects, including renal impairment and ketoacidosis, increases. For this reason, Jardiance is contraindicated for patients with an eGFR below 30, and it is essential for healthcare providers to regularly monitor kidney function before and during treatment. Patients with moderate to severe renal impairment, end-stage renal disease, or those on dialysis require alternative treatments for glycemic control.
It is critical to align medication choices with a patient's renal function to avoid adverse effects and ensure the safest and most effective management of type 2 diabetes. This underscores the importance of personalized medicine and monitoring in the treatment of chronic conditions such as diabetes.